Follow the people · Insider
Eric Devroe
Eric Devroe files insider transactions with the SEC as a chief operating officer of Acrivon Therapeutics (ACRV). We hold 2 disclosed purchases and sales filed since 16 November 2022, 1 of them in the last 90 days.
- Files forACRV
- Disclosed buys and sells2 in all, 1 in the last 90 days
- Last disclosure20 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 14 November 2022 — 18 August 2026Chief Operating Officer · Acrivon Therapeutics (ACRV)26 Form 4 lines · source: SEC Form 4
Everything they disclosed
26 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 604 shares of Acrivon TherapeuticsSEC Form 420 August 2026Common Stock · traded 18 August 2026 · filed 20 August 2026
- was granted 72,981 shares of Acrivon TherapeuticsSEC Form 420 May 2026Common Stock · traded 18 May 2026 · filed 20 May 2026
- had shares withheld for tax on 613 shares of Acrivon TherapeuticsSEC Form 418 May 2026Common Stock · traded 14 May 2026 · filed 18 May 2026
- was granted 186,728 shares of Acrivon Therapeutics (a derivative holding)SEC Form 43 March 2026Stock Option (Right to Buy) · traded 1 March 2026 · filed 3 March 2026
- was granted 186,728 shares of Acrivon Therapeutics (a derivative holding)SEC Form 43 March 2026Stock Option (Right to Buy) · traded 1 March 2026 · filed 3 March 2026
- had shares withheld for tax on 723 shares of Acrivon TherapeuticsSEC Form 418 February 2026Common Stock · traded 14 February 2026 · filed 18 February 2026
- had shares withheld for tax on 723 shares of Acrivon TherapeuticsSEC Form 418 February 2026Common Stock · traded 14 February 2026 · filed 18 February 2026
- ▲ bought on the open market 10,000 shares of Acrivon TherapeuticsSEC Form 415 January 2026Common Stock · traded 13 January 2026 · filed 15 January 2026
- ▲ bought on the open market 10,000 shares of Acrivon TherapeuticsSEC Form 415 January 2026Common Stock · traded 13 January 2026 · filed 15 January 2026
- had shares withheld for tax on 613 shares of Acrivon TherapeuticsSEC Form 418 November 2025Common Stock · traded 14 November 2025 · filed 18 November 2025
- had shares withheld for tax on 613 shares of Acrivon TherapeuticsSEC Form 418 August 2025Common Stock · traded 14 August 2025 · filed 18 August 2025
- had shares withheld for tax on 613 shares of Acrivon TherapeuticsSEC Form 416 May 2025Common Stock · traded 14 May 2025 · filed 16 May 2025
- was granted 140,540 shares of Acrivon Therapeutics (a derivative holding)SEC Form 44 March 2025Stock Option (Right to Buy) · traded 1 March 2025 · filed 4 March 2025
- had shares withheld for tax on 724 shares of Acrivon TherapeuticsSEC Form 419 February 2025Common Stock · traded 14 February 2025 · filed 19 February 2025
- was granted 90,090 shares of Acrivon Therapeutics (a derivative holding)SEC Form 427 November 2024Stock Option (Right to Buy) · traded 1 March 2024 · filed 27 November 2024
- had shares withheld for tax on 613 shares of Acrivon TherapeuticsSEC Form 418 November 2024Common Stock · traded 14 November 2024 · filed 18 November 2024
- had shares withheld for tax on 613 shares of Acrivon TherapeuticsSEC Form 416 August 2024Common Stock · traded 14 August 2024 · filed 16 August 2024
- exercised options over 10,000 shares of Acrivon Therapeutics (a derivative holding)SEC Form 421 May 2024Stock Option (Right to Buy) · traded 17 May 2024 · filed 21 May 2024
- exercised options over 10,000 shares of Acrivon TherapeuticsSEC Form 421 May 2024Common Stock · traded 17 May 2024 · filed 21 May 2024
- had shares withheld for tax on 613 shares of Acrivon TherapeuticsSEC Form 416 May 2024Common Stock · traded 14 May 2024 · filed 16 May 2024
- had shares withheld for tax on 723 shares of Acrivon TherapeuticsSEC Form 416 February 2024Common Stock · traded 14 February 2024 · filed 16 February 2024
- had shares withheld for tax on 2,450 shares of Acrivon TherapeuticsSEC Form 416 November 2023Common Stock · traded 14 November 2023 · filed 16 November 2023
- exercised options over 9,225 shares of Acrivon Therapeutics (a derivative holding)SEC Form 46 June 2023Stock Option (Right to Buy) · traded 5 June 2023 · filed 6 June 2023
- exercised options over 9,225 shares of Acrivon TherapeuticsSEC Form 46 June 2023Common Stock · traded 5 June 2023 · filed 6 June 2023
- was granted 100,150 shares of Acrivon Therapeutics (a derivative holding)SEC Form 416 November 2022Stock Option (Right to Buy) · traded 14 November 2022 · filed 16 November 2022
- was granted 33,383 shares of Acrivon TherapeuticsSEC Form 416 November 2022Common Stock · traded 14 November 2022 · filed 16 November 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.